Caris Life Sciences, Inc.

Fundamentals7.0
Price Action6.0
News Sentiment7.0
AI Rating
7.0

Key Drivers

  • Strong liquidity
  • Preferred burden
  • Mixed earnings

AI
AI Summary

7.0

CAI has moved from pre-commercial speculation to a real operating story with 79% revenue growth, positive free cash flow, and $821M cash, so the key question is now execution—whether it can turn its broadening pipeline into durable reimbursement-backed adoption fast enough to justify its still-demanding valuation.

ExecutionRisk
ValuationRisk
GrowthOpportunity

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

7.0

Key Financial Insights:

  • Strong liquidity
  • Preferred burden
  • Mixed earnings

CAI has strong liquidity and cash generation with a net cash position, but recurring GAAP losses and heavy preferred dividends continue to pressure common shareholders.

Liquidity
Losses

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Higher highs
  • Support holding
  • Pullback risk

CAI has shifted from a downtrend to a constructive last month recovery, but it needs to hold $17.30-$17.60 and clear $18.70-$18.75 to confirm more upside while avoiding a short-term pullback.

Bullish
Watch
Support Level: $17.30-$17.60
Resistance Level: $18.70-$18.75

Fast run-up from $15.48 to $18.75, then a quick dip to $18.30, signals short-term stretch

Sentiment & News

7.0

Key News Insights:

  • Market visibility
  • Shareholder returns
  • Product launch

CAI's June–July headlines highlighted stronger market visibility, shareholder returns, a new government contract, and the launch of Caris Detect, signaling expanding commercial momentum.

growth
innovation

These developments should support sentiment by improving brand recognition, broadening access to capital, and reinforcing CAI's growth narrative